Table 2.
Adverse events of three regimes.
| N (%) | BRAFi | BRAFi+MEKi | BRAFi+PD-1 antibody | |||
|---|---|---|---|---|---|---|
| N = 12 | N = 12 | N = 19 | ||||
| Grade | Any* | III-IV | Any* | III-IV | Any* | III-IV |
| Any adverse event | 12 (100) | 4 (33.3) | 12 (100) | 3 (25.0) | 19 (100) | 11 (57.9) |
| Dermatological events | ||||||
| Rash | 10 (83.3) | 2 (16.7) | 8 (66.7) | 1 (8.3) | 16 (84.2) | 7 (36.8) |
| Palmo–plantar erythrodysesthesia | 10 (83.3) | 0 | 2 (16.7) | 0 | 8 (42.1) | 2 (10.5) |
| Alopecia | 7 (58.3) | 0 | 0 | 0 | 6 (31.6) | 0 |
| Pruritus | 6 (50.0) | 2 (16.7) | 6 (50.0) | 1 (8.3) | 12 (63.2) | 3 (15.8) |
| Photosensitivity reaction | 3 (25.0) | 0 | 0 | 0 | 6 (31.6) | 0 |
| Keratocanthoma | 2 (16.7) | 0 | 0 | 0 | 8 (42.1) | 0 |
| Musculoskeletal events | ||||||
| Arthralgia | 7 (58.3) | 2 (16.7) | 4 (33.3) | 1 (8.3) | 16 (84.2) | 4 (21.1) |
| Myalgia | 5 (41.7) | 0 | 3 (23.1) | 0 | 14 (53.8) | 1 (3.8) |
| Gastrointestinal events | ||||||
| Diarrhea | 3 (25.0) | 0 | 1 (8.3) | 0 | 4 (21.1) | 0 |
| Nausea | 3 (25.0) | 0 | 3 (25.0) | 0 | 3 (15.8) | 0 |
| Vomiting | 3 (25.0) | 0 | 2 (16.7) | 0 | 3 (15.8) | 0 |
| General disorders | ||||||
| Fatigue | 4 (33.3) | 0 | 3 (25.0) | 0 | 9 (47.4) | 0 |
| Pyrexia | 2 (16.7) | 0 | 7 (58.3) | 2 (16.7) | 4 (21.1) | 1 (5.3) |
| Headache | 1 (8.3) | 0 | 2 (16.7) | 0 | 3 (15.8) | 0 |
| Dizziness | 1 (8.3) | 0 | 2 (16.7) | 0 | 3 (15.8) | 0 |
| Investigations/laboratory examinations | ||||||
| Increased alanine aminotransferase level | 3 (25.0) | 1 (8.3) | 4 (33.3) | 1 (8.3) | 7 (36.8) | 0 |
| Increased aspartate aminotransferase level | 1 (8.3) | 1 (8.3) | 3 (25.0) | 1 (8.3) | 4 (21.1) | 0 |
| Increased bilirubin | 0 | 0 | 0 | 0 | 6 (31.6) | 0 |
| Increased blood creatinine | 1 (8.3) | 0 | 3 (25.0) | 0 | 4 (21.1) | 0 |
| Hyperglycemia | 3 (25.0) | 0 | 6 (50.0) | 0 | 5 (26.3) | 0 |
| Pulmonary events | ||||||
| Cough | 0 | 0 | 2 (16.7) | 0 | 1 (5.3) | 0 |
| Pneumonia | 0 | 0 | 0 | 0 | 1 (5.3) | 0 |
| Endocrine dyscrasia | ||||||
| Hypothyroidism | 0 | 0 | 0 | 0 | 3 (15.8) | 0 |
| Hyperthyroidism | 0 | 0 | 0 | 0 | 1 (5.3) | 0 |
Any*, any grade; AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTC, common toxicity criteria; BRAFi, BRAF inhibitor; MEKi, MEK inhibitor.